This announcement is a separate document:
Novartis AG | 6-K: Novartis Scemblix® Shows Superior Major Molecular Response (Mmr) Rates Vs. Standard-of-Care Tkis in Phase Iii Trial for Newly Diagnosed Patients with Chronic Myeloid Leukemia
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it